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Toxicities of Ethylene Glycol
and Ethylene Glycol Monoethyl Ether
in Fischer 344/N Rats and B6C3F1 Mice
by Ronald L. Melnick*
The toxicities of ethylene glycol (EG) and ethylene glycol monoethyl ether (EGEE) were studied in
Fischer 344/N rats and B6C3F1 mice. In a 13-week study, EG was administered in feed to groups of 10 rats
and 10 mice of both sexes at dose levels of 0 (control), 0.32, 0.63, 1.25, 2.5 and 5.0%. Kidney/body weight
ratios were elevated in the 2.5 and 5.0c dose groups of male and female rats relative to controls, while
serum urea nitrogen and serum creatinine levels were elevated in the two highest dose groups ofmale rats.
Toxic nephrosis and crystal deposits in renal tubules were observed in the 2.5 and 5.0% dose groups ofmale
rats. Crystals were also observed in brains of male rats in the 5.0% dose group. Nephrosis was the only
lesion observed in female rats (5.0% dose group). Mild, compound-related lesions were seen in kidneys
(nephrosis) and livers (centrilobular degeneration) of male mice in the 2.5 and 5.0% dose groups. There
were no adverse effects observed in female mice.
Groups of50 rats and 50 mice ofboth sexes were administered EGEE by gavage in a 2-year study at dose
levels of0 (control), 0.5, 1.0 and 2.0 g/kg body weight. Testicularatrophy was observed in male rats thatdied
early in this study and in the medium- and high-dose male mouse groups. Gross lesions noted at necropsy
indicate that chronic treatment ofrats with EGEE at dose levels of0.5 or 1.0 g/kg body weight caused an
apparent enlargement ofthe adrenalglapd in male rats and interfered withthedevelopment ofspontaneous
lesions ofthe spleen (males and females), pituitary (males and females), testis (males), and subcutaneous
tissue in the mammary gland region (females) that commonly occur in the aging Fischer 344/N rat.
Histopathologic review of this study is in progress.
Introduction
Ethylene glycol (EG) and ethylene glycol monoethyl
ether (2-ethoxyethanol, EGEE) were nominated to the
NationalToxicology Programfortoxicity and carcinoge-
nicity testing because of the large amounts of these
chemicals which are produced each year and because of
the potential for human exposure. EG is used in
antifreeze and coolant mixtures for motor vehicles, in
hydraulic fluids and heat exchangers, and as a solvent in
the production of ethylene glycol esters, ether and
resinous products (1). Production of EG in the United
States in 1980 was estimated at 4.4 billion pounds (2).
EGEE is used largely as a solvent in protective coatings
(lacquers, varnishes, paints, and epoxy coatings) and as
an intermediate in the production of ethylene glycol
monoethyl ether acetate (3). It is also used as a solvent
or vehicle for nitrocellulose, printing inks, metal and
glass cleaners, hydraulic fluids, textile and leather
dyeing solutions, varnish removers, lacquer thinners,
and adhesives, as well as an anti-icing additive in
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aviation fuels (3). In 1980, 200 million pounds of EGEE
were produced in the United States (2).
Ethylene Glycol (EG)
Materials and Methods
The subchronic toxicity of EG in rats and mice was
evaluated in a 13-week study conducted at Southern
Research Institute (Birmingham, AL). EGwasadminis-
tered in the diet to groups of 10 male and 10 female
Fischer 344/N rats and 10 male and 10 female B6C3F1
mice. The oral route was selected because it was
considered to be a potential route of human exposure.
EG used in these studies was manufactured by the
Ashland Chemical Company and was shown by gas
chromatographic analyses to be greater than 99% pure.
EG was also shown to be stable in rodent feed, with no
measurable loss occurring after 2 weeks of storage at
25°C. Rats used in this study were obtained from the
Frederick Cancer Research Center and mice were
obtained from Harlan Industries. Rats were about 7
weeks ofage at the start ofthe study and the mice wereR. L. MELNICK
about 9 weeks old at the start of the study. Five
treatment groups plus an untreated control group were
included for each sex and species. The dose levels of
EG, mixed in NIH 07 feed, were 5.0, 2.5, 1.25, 0.63 and
0.32%. City tap water and the dosed feed mixtures or
the control feed diet were available ad libitum
throughout the study. The dose levels selected for this
study were based on dosed feed studies of EG that had
been reported in the scientific literature. Morris et al.
(4) noted that 1% EG in feed had no effect on mortality
of rats after 1 year of treatment, while survival was
decreased at the 2% dose level. Blood (5) saw no effect
on survival of male or female rats fed diets containing
up to 4% EG for 3 months; however, there was 100%
mortality atthe 4% dose levelby 6months. We expected
to reach no observable effect levels in rats or mice fed
diets containing 5.0% to 0.32% EG for 13 weeks.
Results and Discussion
The only deaths observed in this study were in the
highest dose group (5.0%) of male rats (Table 1). The
four deaths occurred during weeks 11, 12 and 13 ofthe
study. There were only nine male rats in the 0.63% dose
group because of a sexing error which was not discov-
ered until week 7 ofthe study. There were no deaths in
any ofthe female rat groups. There was a greater than
10% depression of relative body weight gain for male
rats in the 2.5 and 5.0% dose groups. Relative body
weight data is a measure ofthe average weight gain of
treated animals relative to the average weight gain of
controls. There were no significant effects of EG on
average body weight gain offemale rats. There were no
apparent differences in feed consumption between any
of the male or female rat treatment groups and their
respective control groups.
In the 13-weekstudy in male and female mice (results
not shown), there were no deaths in any ofthe control or
EG treatment groups, and the relative weight gain data
did not show any cleardose-related effect. There was no
evidence of decreased feed consumption for any of the
EG treatment groups and their respective control
groups in the mouse study.
At the necropsy ofanimals which survived to the end
ofthe study, organ weights were measured for the liver,
right kidney, heart, brain, lungs and right testicle. The
mean right kidney weights and kidney/body weight
ratios for male and female rats treated with EG and the
untreated control groups are presented in Table 2.
Significant differences (p < 0.01) in the kidney/body
weightratio were observed forbothmale and female rats
in the 2.5 and 5.0% dose groups relative to the controls.
The mean ratio of thymus to terminal body weight
was significantly decreased (p < 0.05) in male rats in
the 5.0% dose group relative to the controls (results not
shown). There were no otherdose-related organ tobody
weight differences in male or female rats. There were
no differences in organ/body weight ratios in male or
female mouse groups treated with EG relative to
respective controls.
Serum and urine analyses were conducted on all rats
and mice that survived to the end of the study. Blood
Table 1. Mortality and mean body weight changes of Fischer 344/N rats treated with ethylene glycol for 13 weeks.
Males Females
Dose, Relative weight Relative weifht % of feed Mortaitya change, % Mortalitya change, %
0 (control) 0/10 0/10
0.32 0/10 - 2 0/10 +11
0.63 0/9 - 6 0/10 +9
1.25 0/10 - 1 0/10 +6
2.5 0/10 - 13* 0/10 +6
5.0 4/10 - 17t 0/10 +2
aNumber of deaths/number per group.
bRelative weight change = [weight change (dosed group)-weight change (control group)/weight change (control group)] x 100.
*p < 0.05, relative to controls.
tp < 0.01, relative to controls.
Tble 2. Effect of ethylene glycol for 13 weeks on right kidney weight relative to terminal body weight in Fischer 344/N rats.
Males Females
Right kidney Kidney/body wt. Right kidney Kidney/body wt.
Dose, % of feed weight, g ratio x 1000 weight, g ratio x 1000
0 (control) 1.06 ± 0.04 3.09 ± 0.07 0.63 ± 0.01 3.15 ± 0.05
0.32 1.07 ± 0.02 3.12 ± 0.06 0.63 ± 0.03 3.07 ± 0.13
0.63 1.08 ± 0.03 3.25 ± 0.06 0.67 ± 0.02 3.27 ± 0.07
1.25 1.09 ± 0.03 3.15 ± 0.06 0.65 ± 0.02 3.28 ± 0.05
2.5 1.47 ± 0.08 4.59 ± 0.20* 0.70 ± 0.02 3.47 ± 0.06*
5.0 1.62 ± 0.03 5.14 ± 0.22* 0.76 ± 0.02 3.80 ± 0.05*
*p < 0.01, relative to controls.
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samples were obtained from the inferior vena cava of
chloroform anesthetized rats and by cardiac puncture
from similarly anesthetized mice. Serum chemistry
proffles (calcium, chloride, inorganic phosphorous,
sodium, potassium, urea nitrogen, creatinine, total
bilirubin, total protein, albumin, pH, albumin/globulin
ratio, and pCO2) were determined with a CentrifiChem
500 centrifugal analyzer. The only alterations in serum
chemistries in these studies which were statistically
different from controls and which did not exceed normal
limits were serum urea nitrogen and serum creatinine
values (Table 3). The elevated serum urea nitrogen and
creatinine levels in male rats treated with 2.5 or 5.0%
EG in the feed are indicative of EG-induced renal
toxicity in these dose groups. In female rats, serum
urea nitrogen levels were elevated at all dose levels.
However, because of the lack of a dose response in
females and because these values did not exceed normal
limits, we do not attribute any toxicological significance
to these differences. Creatinine levels were decreased in
three ofthe dose groups offemale rats. The meaning of
these findings is not clear since there were no significant
differences in mean body weights between these groups
of animals and the controls. Serum chemistries were
unaffected in male or female mice treated with EG.
There were no changes in urinary parameters (uro-
bilinogen, bilirubin, glucose, pH, blood, ketones, protein,
nitrite, specific gravity, and microscopic appearance) in
any of the treatment groups of rats or mice.
All animals in this study were subjected to acomplete
gross necropsy. Kidneys from the 2.5 and 5.0% dose
groups ofmale rats had a granular, rough and/or pitted
appearance. These were the only gross observations
that appeared to be related to the administration ofEG
in any ofthe treatment groups. Tissues and organs were
dissected from the carcass, fixed in 10% neutral-
buffered formalin, embedded in paraffin, sectioned, and
stained with hematoxylin and eosin. The following
tissues and organs were examined microscopically from
high dose and control animals: gross lesions, tissue
masses, abnormal lymph nodes, mandibular or mesen-
tericlymphnodes, salivarygland, thyroid, parathyroids,
small intestine, colon, liver, gall bladder (mice only),
prostate/testes or ovaries/uterus, lungs and mainstem
bronchi, heart, esophagus, stomach, brain, thymus,
trachea, pancreas, spleen, kidneys, adrenal glands,
urinary bladder, pituitary gland, mammary gland, and
sternebrae, femur or vertebrae including marrow. Any
tissue or organ that was affected in the high dose
groups was examined from lower dose animals until a no
observable effect level was reached.
Chemically induced kidney lesions were observed in
all male rats fed diets containing 2.5 or 5.0% EG (Table
4). Damaged kidneys contained deposits oftransparent,
doubly refractive crystals typical of calcium oxalate.
Crystals were located mainly within tubular lumens in
the renal cortex and were occasionally found in tubules
in the medulla. Similarly appearing crystals were
observed in the urinary bladder or urethral lumen of
three of the highest dose (5.0%) male rats.
In male rats treated with EG, lesions of toxic
nephrosis were superimposed on the background of
minimal chronic nephropathy which is commonly seen in
untreated male Fischer344 rats. Severe toxic nephrosis
Table 3. Effect of ethylene glycol for 13 weeks on serum urea nitrogen and creatinine levels in Fischer 344/N rats.
Urea nitrogen values, mg/dL Creatinine values, mg/dL
Dose, % of feed Males Females Males Females
O (control) 17.0 ± 1.0 15.3 ± 0.7 0.73 ± 0.03 0.64 ± 0.06
0.32 22.3 ± 0.9 20.5 ± 0.7t 0.44 ± 0.03* 0.40 ± 0.05t
0.63 23.9 ± 0.6 18.8 ± 0.9t 0.81 ± 0.03 0.70 ± 0.05
1.25 20.8 ± 1.0 19.8 ± 0.5t 0.80 ± 0.02 0.67 ± 0.05
2.5 39.3 ± 2.8k 21.3 ± 0.7t 0.97 ± 0.07* 0.43 ± 0.03t
5.0 114.3 ± 14.0k 20.4 ± 0.5t 2.37 + 0.29t 0.45 ± 0.04k
*p < 0.05, relative to controls.
tp < 0.01, relative to controls.
Table 4. Microscopic lesions in Fischer 344/N rats treated with ethylene glycol for 13 weeks.
Mean severity (number of animals with lesion)a
Males
Dose, Renal tubules, Brain Females,
% of feed Nephrosis crystals crystals nephrosis
0 (control) 0.9 (9) 0 (0) 0 (0) 0 (0)
0.32 0.8 (8) 0 (0) 0 (0) NEb
0.63 1.0 (9) 0 (0) 0 (0) NE
1.25 0.9 (9) 0 (0) 0 (0) 0 (0)
2.5 3.0(10) 3.0(10) 0 (0) 0 (0)
5.0 4.0(10) 4.0(10) 2.0(10) 2.0(10)
aSeverity of lesion: 1 = minimal; 2 = mild; 3 = moderate; 4 = severe.
bNot examined.
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was diagnosed in the 5.0% dose group and moderate
toxic nephrosis in the 2.5% dose group. Toxic nephrosis
in the high dose groups involved distention and dilation
of renal tubules, necrosis and regeneration of tubule
epithelium, thickening of basement membranes, and
fibrosis. The lumen of some tubules contained necrotic
epithelial cells or aggregates ofneutrophils. There was
multifocal infiltration of lymphocytes, especially in
areas of fibrosis.
Toxic lesions in the kidneys offemale rats in the 5.0%
dose group weremultifocal andtended tobesubcapsular.
The cytoplasm of tubular lining cells was vacuolated,
the nuclei were enlarged, and affected tubules were
commonly surrounded by inflammatory cells. However,
crystals such as those seen in the kidneys of treated
male rats were not observed inthe kidneys offemale rats.
The brains of male rats in the 5.0% dose group
contained clusters of transparent, doubly refractive
crystals typical of calcium oxalate. There was no
significant tissue response to the crystals.
Renal lesions diagnosed as mild toxic nephrosis were
observed in about half the male mice in the 5.0% dose
group and one mouse in the 2.5% dose group (Table 5).
These lesions were characterized as tubular dilation,
cytoplasmic vacuolization, and regenerative hyperplasia
with piling up of nuclei. The lesions were focal and
randomly distributed. There was no evidence ofcrystal
formation in the affected tubules. Cytoplasmic vacuo-
lization in epithelial cells ofthe convoluted tubules was
seen in scattered foci in the treated and control groups
ofmale mice. This lesion was slightly more severe in the
highest dose group and may be compound-related.
There were no adverse effects observed in female mice
at any of the dose levels.
A degenerative change was present in the livers ofall
the male mice in the 5.0 and 2.5% dose groups. This
change was characterized by the accumulation of an
eosinophilic hyaline material that was not birefringent
in the cytoplasm of hepatocytes adjacent to or close to
central veins.
The objectives of these subchronic studies were to
characterize dose-related toxic effects from repeated
exposure to EG and to provide a basis for selection of
dose levels for 2-year chronic studies. The 1.25% dose
level appears tobe ano-effect levelfor EG-induced renal
toxicity (toxic nephrosis and crystals deposited in the
kidney) in male rats treated for 13 weeks. This dose
level corresponds to 0.6 to 1.0 g/kg/day. In a chronic
study conducted by Union Carbide Corp. (6), renal
tubular lesions were seen in the 1 g/kg dose group of
male rats at a 6-month sacrifice, while calcium oxalate
crystalswith associated chronic nephritis were observed
in male rats treated at this dose level for 12 months. In
Blood's study (4), there was 100% mortality in a group
ofmale rats fed diets containing 1% EG for 24 months;
oxalate stones were observed in the kidneys of 11 ofthe
16 animals in that group. EG-induced renal toxicity in
male rats is apparently progressive, and therefore, in
order to insure good survival in a 2-year study, the
maximum dose level for male rats should be somewhat
less than 1%. Toxic lesions in the kidneys offemale rats
were observed microscopically only in the 5.0% dose
group. Therefore, amaximumdoselevelof2. 5% appears
to be suitable for a 2-year study in female rats. That
dose level corresponds to 1.0 to 1.5 g/kg/day. Dose levels
used in the Union Carbide study (6) included 0.2
glkg/day for males and 1.0 g/kg/day for females. Since
these dose levels appear to be adequate for an evalua-
tion of the potential carcinogenicity of EG in rats, the
NTP did not consider it necessary to perform a 2-year
study of EG in rats.
In male mice, the no observable effect level forkidney
and liverlesions produced by EG is 1.25%. However, the
effects in the 2.5% dose group were considered to be
minimal to mild and probably not life-threatening.
There were no adverse effects seen in female mice at
any of the dose levels (7). A 2-year study of EG
administered in feed to groups of 60 B6C3F, male and
female mice is in progress at Southern Research
Institute. The dose levels for male mice are 0 (control),
0.625, 1.25 and 2.5%, while the dose levels for female
mice are 0 (control), 1.25, 2.5 and 5.0%.
Ethylene Glycol Monoethyl Ether
(EGEE)
Materials and Methods
EGEE used in the subehronic and chronic studies
conducted at Gulf South Research Institute (New
Iberia, LA) was manufactured by Union Carbide
Tble 5. Microscopic lesions in male B6C3F1 mice treated with ethylene glycol for 13 weeks.
Mean severity (number of animals with lesion)a
Kidney Liver,
Dose, cytoplasmic centrilobular
% of feed Nephrosis vacuolization degeneration
0 (control) 0 (0) 0.8 (6) 0 (0)
0.32 NEb NE NE
0.63 NE NE NE
1.25 0 (0) 0.5 (3) 0 (0)
2.5 0.2 (1) 1.0 (8) 1.6(10)
5.0 1.1 (5) 2.0 (9) 2.4(10)
aSeverity of lesion: 1 = minimal; 2 = mild; 3 = moderate; 4 = severe.
bNot examined.
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Corporation. The purity ofthe bulk chemical was shown
by vapor phase chromatography to be greaterthan 99%.
In addition the chemical was shown to be stable in
water. The route of administration originally selected
for treating rats and mice with EGEE was dosed water.
In a 14-day repeated dose study in which EGEE was
administered in drinking water at dose levels ranging
from 0.63% to 10%, there was a depression in weight
gain in rats at all dose levels and a concomitant decrease
in water consumption. Because of a concern that a
palatability problem might obscure any toxicity due to
the chemical treatment, the route ofadministration was
changed from dosed water to gavage in a water vehicle.
Results and Discussion
Mortality data fromthe 14-dayrepeated dose study of
EGEE administered by gavage to groups offive male or
five female F344/N rats or B6C3F1 mice are presented
in Table 6. The treatment with EGEE was five times
per week for 2 weeks. In each of these studies, there
was 100% mortality at the 5.0 g/kg dose level and no
mortality at the 1.25 g/kg dose level. These results are
in line with LD50 values which were reported to vary
from 3.0 to 5.5 g/kg body weight in rats (7-10) and from
4.0 to 4.8 g/kg body weight in mice (7,10).
A 2-year gavage study of EGEE dissolved in deion-
ized water was conducted in Fischer 344/N rats and
B6C3F1 mice. Rats and mice of both sexes were
administered EGEE at dose levels of0 (control), 0.5, 1.0
or 2.0 g/kg body weight. Gavage volumes were adjusted
to the weight ofthe animals to provide 5 mL/kg for rats
and 10 mL/kg for mice. Rats were obtained from the
Charles River Breeding Laboratories (Portage, MI) and
were about 7 weeks of age when placed on the study,
i.e., the age when they received their first dose. Mice
were obtained from Charles River Breeding Labora-
tories (Stoneridge, NY) and were about 8 weeks of age
when they received their first dose. For both species
and sexes, animals were separated into various weight
classes and randomly distributed into treatment and
control groups. Rats and mice were housed five per
cage. Treatment and control groups contained 50 ani-
mals per sex per species. EGEE solutions or deionized
water were administered to the animals five times per
week for 103 consecutive weeks. This was followed by a
1-week observation period. City tap water and NIH 07
diet were available ad libitum throughout the study.
The environmentally controlled animal rooms had aver-
age temperatures between 72 and 76°F and the relative
humidity varied between 40 and 70%. Filtered fresh air
was provided at the rate of 12 room changes per hour.
Fluorescent lighting was provided on a cycle of 12 hr on
and 12 hr off. Animals were checked twice daily for
mortality and signs of morbidity. Individual animal
body weights were measured weekly for the first 13
weeks of the study and then monthly until the end
of the study. Animals were also examined weekly for
clinical signs.
Moribund animals and animals that survived to the
end of the study were killed by exsanguination while
under phenobarbital anesthesia and immediately sub-
jected to a complete necropsy. Organs and tissues from
all animals were preserved in 10% neutral-buffered
formalin, embedded in paraffin, sectioned and stained
with hematoxylin and eosin. The same tissues listed in
the ethylene glycol studies were examined microscopi-
cally from all animals in this study.
Kaplan-Meier survival curves for the 2-year studies
of EGEE are shown in Figures 1-4. The most obvious
effect is the marked reduction in survival of the high
dose groups, i.e., the 2000 mg/kg or2 g/kg dose groups.
As a consequence of the high mortality rates, the
high-dose groups for both sexes of both species were
terminated at 17 to 18 weeks of the study. The control
and other treatment groups, the 1.0 and 0.5 g/kg dose
groups, were continued onthe studyuntil the scheduled
terminal sacrifice. Statistical analysis (11) of the sur-
vival data showed that the survival ofthe medium-dose
group of male rats (1000 mg/kg dose group) was
significantly reduced (p < 0.05) in comparison to the
survival of the control group (Fig. 1). Survival of the
low dose group was not significantly different from the
survival of the control group. At the end of the study
there were 30 survivors in the control group, 38
survivors in the low-dose group, and 18 survivors in the
medium-dose group. Survival ofthemedium-dose group
of female rats (Fig. 2) was not significantly different
from survival ofthe control group, while survival ofthe
low-dose group was significantly increased (p < 0.01) in
comparison to survival ofthe control group. At the end
of this study there were 26 survivors in the control
group, 46 survivors in the low-dose group, and 25
survivors in the medium-dose group.
For male or female mice there were no significant
differences in survival between either the medium- or
Table 6. A 14-day study of ethylene glycol monoethyl ether administered by oral gavage to F344/N rats and B6C3F1 mice:
mortality data.
Number of deaths/number per group
Dose, g/kg body wt. Male rats Female rats Male mice Female mice
O (control) 0/5 0/5 0/5 0/5
0.3 0/5 0/5 0/5 0/5
0.6 0/5 0/5 0/5 0/5
1.25 0/5 0/5 0/5 0/5
2.5 3/5 4/5 0/5 2/5
5.0 5/5 5/5 5/5 5/5
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FIGURE 1. Kaplan-Meier survival curves for male rats administered ethylene glycol monoethyl ether by gavage.
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Table 7. Mean body weights of F344/N rats and B6C3F1 mice treated with ethylene glycol monoethyl ether
for 2 years.
Mean body weight at 104 weeks, g (% of control)
Dose, g/kg body wt. Male rats Female rats Male mice Female mice
0 (control) 421 315 44 40
0.5 339 (81) 239 (76) 40 (91) 38 (95)
1.0 304 (72) 225 (71) 41 (93) 39 (98)
low-dose groups and the respective control groups
(Figs. 3 and 4). At the end of the study of male mice
there were 36 survivors in the control group, 28
survivors in the low-dose group, and 33 survivors in the
medium-dose group. At the end of the study of female
mice there were 36 survivors in the control group, 38
survivors in the low-dose group, and 32 survivors in the
medium-dose group.
Dose-related depressions in mean body weight were
apparent in both the male and female rat studies (Table
7). The differences in mean body weight between the
control and treatment groups became apparent at about
15 weeks, and continued throughout the course of the
study. The mean body weights of the male or female
mouse groups treated with EGEE did not appear to
differ markedly from the mean body weights of the
respective control groups (Table 7).
Two types of gross lesions were commonly seen in the
high-dose rats and mice that were terminated at 17to 18
weeks ofthe study due tohigh earlymortality (Table 8).
First, the testes of the high-dose male rats and mice
were generally decreased in size. Stenger et al. (10) and
Nagano et al. (12) reported that EGEE causes testic-
ular atrophy in male rats and mice. Microscopic exami-
nation ofthe testes ofthe high-dose male rats and mice
confirmed the diagnosis of testicular atrophy in the
present study. Second, stomach ulcers were observed in
many of the high-dose male and female rats and the
high-dose male mice. These lesions were probably a
major contributing cause of death in the high-dose
groups. There were no consistent gross lesions seen in
the high-dose female mice.
Changes in the frequencies of gross lesions in the
low-and medium-dose groups ofrats and mice relative to
the respective control groups in the 2-year study of
EGEE are summarized in Table 9. There was an
increased incidence of enlarged adrenal glands in male
rats treated with EGEE in comparison to control male
Table 8. Gross lesions in high dose (2.0 g/kg) Fischer 344/N rats or
B6C3Fj mice treated with ethylene glycol monoethyl ether.
Species/sex Lesion
Rats, male Testis, reduced in size
Stomach, ulceration
Rats, female Stomach, ulceration
Mice, male Testis, reduced in size
Stomach, ulceration
Mice, female None
rats. A comparable change in treated female rats or in
treated male or female mice was not observed at
necropsy. Also, there were decreased incidences of
enlarged spleens in the male and female rat groups
treated with EGEE in comparison to the incidences in
the control male and female rat groups. Pituitary
changes, including enlargement, presence of a mass,
and/ordiscoloration, which are relatively common inthe
aging Fischer 344/N rat were decreased in incidence in
both male and female rat groups treated with EGEE
relative to their respective control groups. Subcuta-
neous tissue masses in the mammary gland region were
decreased in incidence in female rats treated with
EGEE in comparison to control female rats. In the male
Fischer 344/N rat, the common testicular changes
which include enlarged testis with or without evidence
of a mass were decreased in incidence in rats treated
with EGEE compared to controls. Additionally, testis
size was generally reduced in male mice treated with
EGEE relative to control male mice. The histopatho-
logic review of this study is in progress.
The following conclusions were made from the 2-year
study of EGEE. Repeated administration of EGEE at
the 2.0 g/kgdose level was lethal to rats and mice. Early
mortality in the high-dose groups of rats and mice
appeared to be due to stomach ulcers. EGEE caused
testicular atrophy in male rats and mice. This effect was
Table 9. Gross lesions in Fischer 344/N rats or B6C3F1 mice treated with ethylene glycol monoethyl ether for 2 years.
Lesion Male rats Female rats Male mice Female mice
Adrenal: enlarged t
Spleen: enlarged 4 4
Pituitary: enlarged, mass
and/or discoloration 4 l
Subcutaneous tissue: mass
in mammary gland region c
Testis: enlarged and/or mass 4
reduced in size t
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apparent in high-dose male rats which died early in the
2-year study and in the medium- and high-dose male
mice. Gross observations indicate that chronic treat-
ment with EGEE at dose levels of 0.5 or 1.0 g/kg body
weight caused an apparent enlargement of the adrenal
gland in male rats and interferes with the development
of spontaneous gross lesions of the spleen, pituitary,
and testis that commonly occur in the aging male
Fischer 344 rat. Chronic treatment with EGEE also
caused a decrease in the incidences of enlarged spleens
and pituitaries and of subcutaneous masses in the
mammary gland region in the aging female Fischer 344
rat.
The author wishes to thank Ms. Nancy Mitchell for dedicated
assistance in preparing this manuscript.
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